Literature DB >> 2843199

Antihypertensive efficacy of lisinopril. Ambulatory blood pressure monitoring.

P K Zachariah1, S G Sheps, G L Schwartz, A Schirger, D M Ilstrup, C R Long, C A Carlson.   

Abstract

Noninvasive automatic ambulatory blood pressure monitoring during 24 hours in eight patients with moderate hypertension was used to determine the blood pressure response to lisinopril, an angiotensin-converting enzyme inhibitor. Office, 24-hour ambulatory, awake ambulatory, and sleep ambulatory diastolic blood pressures were decreased from 108 +/- 3, 98 +/- 8, 101 +/- 7, and 87 +/- 14 mm Hg, respectively, at baseline to 83 +/- 4 (P less than or equal to 0.0001), 82 +/- 7 (P less than 0.0001), 84 +/- 7 (P less than 0.0001), and 73 +/- 9 mm Hg (P less than 0.005), respectively, after 20 weeks of lisinopril treatment (dose range, 40 to 80 mg once daily). The diastolic blood pressure loads (percentages of ambulatory diastolic blood pressures more than 90 mm Hg) during 24 hours and during awake hours were 74% +/- 19% and 83% +/- 15%, respectively, at baseline and 24% +/- 19% (P less than 0.0001) and 29% +/- 21% (P less than 0.0001), respectively, during treatment. Heart rate was not altered by lisinopril. In conclusion, lisinopril is an effective antihypertensive agent for the treatment of moderate hypertension, and ambulatory blood pressures and diastolic blood pressure loads are useful for evaluating therapy for hypertension.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2843199     DOI: 10.1093/ajh/1.3.274s

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  3 in total

Review 1.  The Hypertension in the Very Elderly Trial (HYVET). Rationale, methodology and comparison with previous trials.

Authors:  C J Bulpitt; A E Fletcher; A Amery; J Coope; J G Evans; S Lightowlers; K O'Malley; A Palmer; J Potter; P Sever
Journal:  Drugs Aging       Date:  1994-09       Impact factor: 3.923

2.  Comparison of quinapril and atenolol as single drugs or in combination with hydrochlorothiazide in moderate to severe hypertensives, using automated ambulatory monitoring.

Authors:  Y Lacourcière; J Lefebvre; P Provencher; L Poirier
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

Review 3.  Trandolapril. How does it differ from other angiotensin converting enzyme inhibitors?

Authors:  F Zannad
Journal:  Drugs       Date:  1993       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.